Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection

Microbes and Infection

Volumn 2, Issue 13, 2000, Pages 1579-1590

  Holland, Steven M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

GM CSF; IFN ; IFN ; IL 12; TNF

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY; CHRONIC GRANULOMATOUS DISEASE; CYTOKINE PRODUCTION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE DEFICIENCY; MYCOBACTERIOSIS; PRIORITY JOURNAL;

EID: 0033694329     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(00)01314-9     Document Type: Review

References (100)

1. Undersogelser angaende spedalskhedens arsager
2. Forsetzung der mittheilung uber ein heilmittel gegen tuberkulose
3. The bacillus of syphilis
4. Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature
5. Mendelian Susceptibility to mycobacterial infection in man
6. Current and future clinical applications of interferon-gamma in host antimicrobial defense
7. Cellular responses to interferon-γ
8. Cytokine and Growth Factor
9. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway
10. Effector mechanisms involved in cytokine-mediated bacteriostasis of Mycobacterium avium infections in murine macrophages
11. Attempts to characterize the mechanisms involved in mycobacterial growth inhibition by gamma-interferon-activated bone marrow macrophages
12. Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice
13. Transient loss of resistance of pulmonary tuberculosis in p47(phox-/-) mice
14. Oxidative and non-oxidative intracellular killing of Mycobacterium avium complex
15. Cytokine modulation of Mycobacterium tuberculosis growth in human macrophages
16. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria
17. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection
18. Disseminated tuberculosis in interferon gamma gene-disrupted mice
19. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide
20. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages
21. Defects in cell-mediated immunity affect chronic, but not innate, resistance of mice to Mycobacterium avium infection
22. Chronic infection due to Mycobacterium intracellulare in mice: Association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma
23. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease (see comments)
24. Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease
25. Interferon-gamma in the management of infectious diseases (clinical conference)
26. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy
27. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients
28. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
29. Thalidomide stimulates T cell responses and interleukin 12 produciton in HIV-infected patients
30. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis
31. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients
32. Idiopathic disseminated bacillus Calmette-Guerin infection: A French retrospective study
33. Disseminated bacille Calmette-Guerin disease after vaccination: Case report and review
34. Interferon-gamma Mycobacterium avium-intracellulare infection
35. Interferon-gamma treatment for Mycobacterium avium-intracellular complex bacillemia in patients with AIDS
36. Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: Abnormal IL-12 regulation
37. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report
38. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency
39. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection
40. Familial disseminated atypical mycobacterial infection in childhood: A human mycobacterial susceptibility gene?
41. Familial disseminated infection due to atypical mycobacteria with childhood onset
42. A human IFN-GR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection
43. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection
44. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency
45. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients
46. Nontuberculous mycobacterial pulmonary disease
47. Infection with Mycobacterium avium complex in patients without predisposing conditions
48. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex
49. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome
50. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis
51. Analyses of the NRAMP1 and IFN-gammaR1 genes in women with Mycobacterium avium-intracellulare pulmonary disease
52. Familial pulmonary Mycobacterium avium complex disease
53. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: Diagnostic and management limitations
54. Organ specific cytokine therapy: Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon gamma to the human lung
55. Aerosolized interferon gamma for Mycobacterium avium-complex lung disease
56. Use of adjunctive treatment with interferon-gamma in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain
57. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol
58. Stimulation with cytokines enhances penetration of azithromycin into human macrophages
59. Immunochemotherapy for intracellular Leishmania donovani infection: Gamma interferon plus pentavalent antimony
60. Effect of treatment with interferon-gamma alone in visceral leishmaniasis
61. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway
62. Selective expression of an interleukin-12 receptor component by human T helper 1 cells
63. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis
64. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: Long-term follow-up
65. Lysis of mycobacteria-infected monocytes by IL-2-activated killer cells: Role of LFA-1
66. Cytokine activation of killer cells in mycobacterial immunity
67. Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages
68. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor
69. The relative impact of bacterial virulence and host genetic background on cytokine expression during Mycobacterium avium infection of mice
70. Leprosy and cell-mediated immunity
71. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy
72. The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2
73. Rational immunotherapy with interleukin 2
74. Intradermal recombinant interleukin 2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy
75. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy
76. Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis
77. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients
78. Controlled trial of interleukin 2 infusions in patients infected with the human immunodeficiency virus
79. Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: Role of phagocytosis
80. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha
81. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium
82. Old mice are able to control low-dose aerogenic infections with Mycobacterium tuberculosis
83. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis
84. Defective monocyte costimulation for interferon gamma production in familial disseminated Mycobacterium avium complex infection
85. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection
86. Successful IL-12 therapy in interferon gamma refractory pulmonary M. abscessus
87. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production
88. Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex
89. Production of granulocyte-macrophage colony-stimulating factor (GM-CSF) by monocytes and large granular lymphocytes stimulated with Mycobacterium avium-M. intracellulare: Activation of bactericidal activity by GM-CSF
90. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model
91. Dysfunctional monocytes from a patient with disseminated Mycobacterium kansasii infection are activated in vitro and in vivo by GM-CSF
92. Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor
93. Isolated cutaneous response to granulocyte-monocyte colony stimulating factor in fatal idiopathic disseminated bacillus Calmette-Guerin infection
94. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection
95. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice
96. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis
97. Immunomodulation by thalidomide and thalidomide analogues
98. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon gamma receptor (IFN-gammaR1) deficiency: Mutational analysis and evaluation of therapeutic options
99. Effector cells of both nonhemopoietic and hemopoietic origin are required for interferon (IFN)-gamma- and tumor necrosis factor (TNF)-alpha-dependent host resistance to the intracellular pathogen, Toxoplasma gondii